ERBB2 and breast carcinoma: It is worth noting that trastuzumab could also inhibit the proliferation of two breast cancer cell lines but its inhibitory intensity was much weaker than anti-HER2 IVIg (p = 3.05 × 10−6 for SK-BR-3 cells and p = 2.32 × 10−10 for BT-474 cells).